fingolimod — Medica

relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing remitting disease, active secondary progressive disease)

Initial criteria

Patient has a relapsing form of multiple sclerosis (clinically isolated syndrome, relapsing remitting disease, or active secondary progressive disease); AND
age ≥ 10 years; AND
Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

Patient has a relapsing form of multiple sclerosis (clinically isolated syndrome, relapsing remitting disease, or active secondary progressive disease); AND
age ≥ 10 years; AND
Patient experienced a beneficial clinical response when assessed by at least one objective measure (e.g., stabilization or reduced worsening in disease activity by MRI, reduction in relapses, stabilization or improvement in EDSS, NEDA-3/NEDA-4 achievement, fatigue or walking test improvement, MSFC score improvement, or slowed brain volume loss) OR Patient experienced stabilization, slowed progression, or improvement in at least one symptom (motor function, fatigue, vision, bowel/bladder function, spasticity, walking/gait, or pain/numbness/tingling); AND
Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

1 year